Noubar Afeyan - Net Worth and Insider Trading

Noubar Afeyan Net Worth

The estimated net worth of Noubar Afeyan is at least $1.3 Billion dollars as of 2024-04-25. Noubar Afeyan is the Director of Moderna Inc and owns about 11,722,969 shares of Moderna Inc (MRNA) stock worth over $1.3 Billion. Noubar Afeyan is the Director, 10% Owner of Seres Therapeutics Inc and owns about 21,586,905 shares of Seres Therapeutics Inc (MCRB) stock worth over $16 Million. Noubar Afeyan is also the Director, 10% Owner of BG Medicine Inc and owns about 1,286,274 shares of BG Medicine Inc (BGMD) stock worth over $129. Details can be seen in Noubar Afeyan's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Noubar Afeyan has not made any transactions after 2024-04-17 and currently still holds the listed stock(s).

Transaction Summary of Noubar Afeyan

To

Noubar Afeyan Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Noubar Afeyan owns 27 companies in total, including Foghorn Therapeutics Inc (FHTX) , Codiak BioSciences Inc (CDAKQ) , and Moderna Inc (MRNA) among others .

Click here to see the complete history of Noubar Afeyan’s form 4 insider trades.

Insider Ownership Summary of Noubar Afeyan

Ticker Comapny Transaction Date Type of Owner
FHTX Foghorn Therapeutics Inc 2020-10-22 10 percent owner
CDAKQ Codiak BioSciences Inc 2020-10-13 10 percent owner
MRNA Moderna Inc 2024-04-10 director & 10 percent owner
EVLO Evelo Biosciences Inc 2018-05-08 director & 10 percent owner
KLDO Kaleido Biosciences Inc 2019-02-27 director & 10 percent owner
RUBY Rubius Therapeutics Inc 2021-03-19 director & 10 percent owner
AXLA Axcella Health Inc 2020-05-18 10 percent owner
TMDX TransMedics Group Inc 2019-05-01 10 percent owner
MCRB Seres Therapeutics Inc 2019-06-18 director
SYRS Syros Pharmaceuticals Inc 2017-08-17 10 percent owner
DNLI Denali Therapeutics Inc 2017-12-07 10 percent owner
QTRX Quanterix Corp 2017-12-06 10 percent owner
SESN Sesen Bio Inc 2016-09-06 10 percent owner
EDIT Editas Medicine Inc 2016-08-11 10 percent owner
RNAC Cartesian Therapeutics Inc 2016-06-21 director & 10 percent owner
BGMD BG Medicine Inc 2015-12-09 director & 10 percent owner
TTOO T2 Biosystems Inc 2014-08-06 10 percent owner
AGIO Agios Pharmaceuticals Inc 2013-07-23 10 percent owner
CNCE Concert Pharmaceuticals Inc 2014-02-12 10 percent owner
BINDQ DNIB Unwind Inc 2013-09-25 director & 10 percent owner
XLRN Acceleron Pharma Inc 2013-09-18 10 percent owner
TTPH Tetraphase Pharmaceuticals Inc 2013-03-25 10 percent owner
AGEN Agenus Inc 2004-05-27 director
SANA Sana Biotechnology Inc 2021-02-03 10 percent owner
SGTX Sigilon Therapeutics Inc 2020-12-03 10 percent owner
OMGA Omega Therapeutics Inc 2021-07-29 director & 10 percent owner
CARM CARISMA Therapeutics Inc 2016-09-06 10 percent owner

Noubar Afeyan Latest Holdings Summary

Noubar Afeyan currently owns a total of 3 stocks. Among these stocks, Noubar Afeyan owns 11,722,969 shares of Moderna Inc (MRNA) as of April 17, 2024, with a value of $1.3 Billion and a weighting of 98.78%. Noubar Afeyan owns 21,586,905 shares of Seres Therapeutics Inc (MCRB) as of June 18, 2019, with a value of $16 Million and a weighting of 1.22%. Noubar Afeyan also owns 1,286,274 shares of BG Medicine Inc (BGMD) as of December 9, 2015, with a value of $129 and a weighting of 0%.

Latest Holdings of Noubar Afeyan

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
MRNA Moderna Inc 2024-04-17 11,722,969 108.85 1,276,045,176
MCRB Seres Therapeutics Inc 2019-06-18 21,586,905 0.73 15,747,647
BGMD BG Medicine Inc 2015-12-09 1,286,274 0.00 129

Holding Weightings of Noubar Afeyan


Noubar Afeyan Form 4 Trading Tracker

According to the SEC Form 4 filings, Noubar Afeyan has made a total of 70 transactions in Moderna Inc (MRNA) over the past 5 years, including 0 buys and 70 sells. The most-recent trade in Moderna Inc is the sale of 15,000 shares on April 17, 2024, which brought Noubar Afeyan around $2 Million.

According to the SEC Form 4 filings, Noubar Afeyan has made a total of 1 transactions in Seres Therapeutics Inc (MCRB) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Seres Therapeutics Inc is the acquisition of 8,888,888 shares on June 18, 2019, which cost Noubar Afeyan around $20 Million.

According to the SEC Form 4 filings, Noubar Afeyan has made a total of 0 transactions in BG Medicine Inc (BGMD) over the past 5 years. The most-recent trade in BG Medicine Inc is the sale of 46,438 shares on December 9, 2015, which brought Noubar Afeyan around $26,005.

Insider Trading History of Noubar Afeyan

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Noubar Afeyan Trading Performance

GuruFocus tracks the stock performance after each of Noubar Afeyan's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Noubar Afeyan is 46.36%. GuruFocus also compares Noubar Afeyan's trading performance to market benchmark return within the same time period. The performance of stocks bought by Noubar Afeyan within 3 months outperforms 1 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Noubar Afeyan's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Noubar Afeyan

Average Return

68.34%

Average return per transaction

Outperforming Transactions

100%

1 out of 1 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 20.31 46.36 64.75 68.34 188.79 3.1
Relative Return to S&P 500(%) 17.66 43.31 55.38 61.59 169.32 -4.89

Noubar Afeyan Ownership Network

Ownership Network List of Noubar Afeyan

No Data

Ownership Network Relation of Noubar Afeyan


Noubar Afeyan Owned Company Details

What does Foghorn Therapeutics Inc do?

Who are the key executives at Foghorn Therapeutics Inc?

Noubar Afeyan is the 10 percent owner of Foghorn Therapeutics Inc. Other key executives at Foghorn Therapeutics Inc include Chief Strategy/Bus Ops Officer Fanny Cavalie , Chief Medical Officer Alfonso Quintas Cardama , and Chief Medical Officer Samuel Agresta .

Foghorn Therapeutics Inc (FHTX) Insider Trades Summary

Over the past 18 months, Noubar Afeyan made no insider transaction in Foghorn Therapeutics Inc (FHTX). Other recent insider transactions involving Foghorn Therapeutics Inc (FHTX) include a net sale of 311,297 shares made by Samuel Agresta , and a net sale of 11,000 shares made by Fanny Cavalie .

In summary, during the past 3 months, insiders sold 11,000 shares of Foghorn Therapeutics Inc (FHTX) in total and bought 0 shares, with a net sale of 11,000 shares. During the past 18 months, 322,297 shares of Foghorn Therapeutics Inc (FHTX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 322,297 shares.

Foghorn Therapeutics Inc (FHTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Foghorn Therapeutics Inc Insider Transactions

No Available Data

Noubar Afeyan Mailing Address

Above is the net worth, insider trading, and ownership report for Noubar Afeyan. You might contact Noubar Afeyan via mailing address: C/o Flagship Pioneering, Inc., 55 Cambridge Parkway, Suite 800e, Cambridge Ma 02142.

Discussions on Noubar Afeyan

No discussions yet.